혈압 측정 기기 시장 : 제품 유형별, 기술별, 접속성별, 휴대성별, 용도별, 최종 사용자별, 유통 채널별 시장 예측(2026-2032년)

The Blood Pressure Monitoring Devices Market is projected to grow by USD 8.49 billion at a CAGR of 8.71% by 2032.

Blood Pressure Monitoring Devices Executive Summary

Blood pressure monitoring devices are becoming essential infrastructure for prevention, diagnosis, treatment titration, and long-term management of hypertension. The World Health Organization reports that about 1.28 billion adults aged 30 to 79 live with hypertension globally, while roughly 46% are unaware of their condition and only about 21% have it controlled. This creates sustained demand for clinically validated blood pressure monitors across hospitals, primary care centers, pharmacies, workplaces, and home healthcare settings.

The industry is shifting from episodic office-based readings to continuous, connected, and patient-centered blood pressure management. Automated upper-arm monitors, ambulatory blood pressure monitoring systems, remote patient monitoring platforms, and validated home blood pressure monitors are increasingly favored because major clinical guidelines support out-of-office measurement to improve diagnostic accuracy and reduce white-coat and masked hypertension risk.

Transformative Shifts Reshaping Blood Pressure Monitoring

The blood pressure monitoring device landscape is being reshaped by three structural forces: the global hypertension burden, the movement of care into the home, and the need for validated digital health workflows. Mercury sphygmomanometers continue to decline because of environmental and safety concerns, while automated oscillometric devices, ambulatory blood pressure monitoring, and connected home monitors gain adoption.

Healthcare systems are prioritizing devices that integrate with electronic health records, telehealth programs, and remote patient monitoring reimbursement models. Buyers are also becoming more selective: clinically validated accuracy, appropriate cuff sizing, arrhythmia detection, ease of use, data privacy, and interoperability now influence procurement decisions as much as price.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is accelerating the transition from measurement-only devices to decision-support ecosystems. AI-enabled algorithms can support signal quality assessment, irregular heartbeat flagging, trend detection, adherence reminders, risk stratification, and clinician dashboards that highlight patients needing intervention. These capabilities are particularly valuable in remote patient monitoring, where large volumes of home blood pressure data can overwhelm care teams.

The cumulative impact of AI will depend on clinical validation, regulatory clearance, bias testing, and transparent performance across age groups, skin tones, pregnancy status, arrhythmias, and comorbidities. For cuffless and wearable blood pressure technologies, AI offers promise, but established standards still require rigorous validation before these tools can replace clinically validated cuff-based monitors for diagnosis or treatment decisions.

Key Regional Insights Across Major Markets

Asia-Pacific represents a high-volume opportunity for blood pressure monitoring devices because China and India carry very large hypertensive populations, Japan has one of the world's oldest populations, and Australia and South Korea have strong digital health adoption. Demand is supported by urbanization, rising cardiometabolic risk, expanding primary care, and consumer familiarity with home health electronics.

North America benefits from guideline-driven use of home and ambulatory blood pressure monitoring, strong telehealth infrastructure, and remote patient monitoring reimbursement pathways. Europe is shaped by strict medical device regulation, aging demographics, pharmacy-based screening, and broad use of validated devices in primary care. Latin America, led by Brazil and Mexico, shows growing demand for hypertension screening and home monitoring, although uneven access, affordability, and continuity of care remain barriers.

The Middle East, especially Gulf health systems, is investing in digital hospitals and chronic disease programs as diabetes, obesity, and hypertension converge. Africa has a substantial underdiagnosis challenge; scalable opportunities center on affordable validated monitors, community screening, solar or battery-resilient devices, and integration with primary healthcare programs.

Key Group Insights for Strategic Positioning

ASEAN markets are moving toward broader home blood pressure monitoring as urban hypertension, pharmacy screening, and mobile health adoption increase, though reimbursement and validation awareness vary by country. The GCC is investing in chronic disease management and digitally connected care, making integrated blood pressure monitoring devices relevant for diabetes, kidney disease, and cardiovascular risk programs.

The European Union emphasizes compliance with the Medical Device Regulation, data protection under GDPR, and adoption of clinically validated devices across public and private care settings. BRICS economies combine large disease burden with price sensitivity, creating demand for scalable, durable, and localized manufacturing models. G7 markets remain centers for innovation, reimbursement design, and evidence generation for connected blood pressure monitoring. NATO countries add demand through military health, occupational screening, and resilient medical supply chain planning.

Country-Level Opportunities and Adoption Signals

In the United States, CDC data show nearly half of adults have hypertension, creating strong demand for validated home monitors and remote patient monitoring. Canada's national surveillance identifies hypertension in roughly one in four adults, supporting pharmacy, primary care, and home-based monitoring. Mexico and Brazil face high cardiometabolic risk and expanding chronic disease programs, although affordability and follow-up capacity remain central adoption factors.

The United Kingdom, Germany, France, Italy, and Spain all face aging populations and high adult hypertension prevalence, making validated automatic blood pressure monitors important for primary care, pharmacies, and self-measurement. Russia's cardiovascular disease burden sustains the need for earlier detection and treatment monitoring.

China has more than 245 million adults with hypertension according to national studies, while India's NFHS-5 shows elevated blood pressure in about 24% of men and 21% of women aged 15 and older. Japan, Australia, and South Korea combine aging demographics with high digital readiness, supporting premium home monitors, ambulatory systems, and connected care models.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically validated upper-arm devices, clear cuff-size options, and compliance with recognized validation protocols such as AAMI/ESH/ISO 81060-2. Product portfolios should distinguish between diagnostic-grade monitors, home-use devices, ambulatory blood pressure monitoring, and wellness-oriented wearables.

Recommended actions include:

• Build interoperability with EHR, telehealth, and remote patient monitoring platforms.
• Publish validation evidence for diverse populations and use cases.
• Design affordability tiers for emerging markets without compromising accuracy.
• Strengthen cybersecurity, consent, and data governance.
• Partner with pharmacies, employers, payers, and community health programs to expand screening and adherence. Research Methodology

This executive summary is based on secondary research from verified public health and regulatory sources, including the World Health Organization, CDC, national health surveys, clinical guideline bodies, medical device regulators, and hypertension societies. The assessment considers disease burden, care-delivery models, device validation standards, reimbursement signals, and regional healthcare infrastructure.

Market interpretation was structured across device type, care setting, technology enablement, geography, and end-user adoption. Insights were triangulated using epidemiological data, policy guidance, regulatory direction, and observable healthcare digitization trends to avoid unsupported market claims, including unsupported sizing or forecasting assumptions.

Conclusion

Blood pressure monitoring devices are central to the global shift from reactive cardiovascular care to proactive chronic disease management. The strongest opportunities are in validated, connected, user-friendly devices that support accurate diagnosis, home monitoring, clinical follow-up, and population health programs.

As hypertension remains underdiagnosed and undertreated worldwide, manufacturers and healthcare partners that combine clinical accuracy, AI-enabled workflow support, affordability, and regulatory credibility will be best positioned to lead the next phase of blood pressure monitoring adoption.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Blood Pressure Monitoring Devices Market, by Product Type

• 7.1. Devices
  • 7.1.1. Sphygmomanometers
    • 7.1.1.1. Mercury Sphygmomanometers
    • 7.1.1.2. Aneroid Sphygmomanometers
  • 7.1.2. Digital Blood Pressure Monitors
  • 7.1.3. Ambulatory Blood Pressure Monitors
• 7.2. Accessories
  • 7.2.1. Blood Pressure Cuffs
  • 7.2.2. Bladders
  • 7.2.3. Bulbs
  • 7.2.4. Valves
  • 7.2.5. Connectors

8. Blood Pressure Monitoring Devices Market, by Technology

• 8.1. Manual
• 8.2. Digital
  • 8.2.1. Oscillometric Technology
  • 8.2.2. Auscultatory Digital

9. Blood Pressure Monitoring Devices Market, by Connectivity

• 9.1. Non Connected Devices
• 9.2. Connected Devices
  • 9.2.1. Bluetooth Enabled
  • 9.2.2. Wi Fi Enabled
  • 9.2.3. Cellular Enabled

10. Blood Pressure Monitoring Devices Market, by Portability

• 10.1. Portable Devices
• 10.2. Non Portable Devices

11. Blood Pressure Monitoring Devices Market, by Application

• 11.1. Hypertension Monitoring
• 11.2. Hypotension Monitoring
• 11.3. Cardiovascular Disease Management
• 11.4. Chronic Disease Management
• 11.5. Fitness & Wellness Monitoring

12. Blood Pressure Monitoring Devices Market, by End User

• 12.1. Ambulatory Care Centers
• 12.2. Clinics
• 12.3. Home Healthcare
• 12.4. Hospitals

13. Blood Pressure Monitoring Devices Market, by Distribution Channel

• 13.1. Offline
• 13.2. Online

14. Blood Pressure Monitoring Devices Market, by Region

• 14.1. Asia-Pacific
• 14.2. North America
• 14.3. Latin America
• 14.4. Europe
• 14.5. Middle East
• 14.6. Africa

15. Blood Pressure Monitoring Devices Market, by Group

• 15.1. ASEAN
• 15.2. GCC
• 15.3. European Union
• 15.4. BRICS
• 15.5. G7
• 15.6. NATO

16. Blood Pressure Monitoring Devices Market, by Country

• 16.1. United States
• 16.2. Canada
• 16.3. Mexico
• 16.4. Brazil
• 16.5. United Kingdom
• 16.6. Germany
• 16.7. France
• 16.8. Russia
• 16.9. Italy
• 16.10. Spain
• 16.11. China
• 16.12. India
• 16.13. Japan
• 16.14. Australia
• 16.15. South Korea

17. Competitive Landscape

• 17.1. Market Concentration Analysis, 2025
  • 17.1.1. Concentration Ratio (CR)
  • 17.1.2. Herfindahl Hirschman Index (HHI)
• 17.2. Recent Developments & Impact Analysis, 2025
• 17.3. Product Portfolio Analysis, 2025
• 17.4. Benchmarking Analysis, 2025

18. Company Profiles

• 18.1. A&D Company Limited
• 18.2. Beurer GmbH
• 18.3. BOSCH + SOHN GmbH u. Co. KG
• 18.4. BPL Medical Technologies Private Limited
• 18.5. Citizen Systems Japan Co Ltd
• 18.6. Contec Medical Systems Co Ltd
• 18.7. ForaCare Suisse AG
• 18.8. GE Healthcare
• 18.9. Greater Goods LLC
• 18.10. Halma plc
• 18.11. iHealth Labs Inc
• 18.12. Koninklijke Philips N V
• 18.13. Microlife Corporation
• 18.14. Nihon Kohden Corporation
• 18.15. Omron Healthcare
• 18.16. Qardio Inc
• 18.17. Riester GmbH
• 18.18. Rossmax International Limited
• 18.19. Smiths Group plc
• 18.20. Spacelabs Healthcare
• 18.21. Spengler
• 18.22. SunTech Medical Inc
• 18.23. Veridian Healthcare
• 18.24. Welch Allyn Inc
• 18.25. Yuwell Jiangsu Yuyue Medical Equipment Co Ltd